Decibel Therapeutics Analysis
| DBTXDelisted Stock | USD 3.08 0.02 0.65% |
Decibel Therapeutics is overvalued with Real Value of 2.95 and Hype Value of 3.08. The main objective of Decibel Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Decibel Therapeutics is worth, separate from its market price. There are two main types of Decibel Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Decibel Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Decibel Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Decibel Stock trading window is adjusted to America/New York timezone.
Decibel |
Decibel Stock Analysis Notes
About 13.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.67. Some equities with similar Price to Book (P/B) outperform the market in the long run. Decibel Therapeutics recorded a loss per share of 2.56. The entity had not issued any dividends in recent years. Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. Decibel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 62 people. To learn more about Decibel Therapeutics call Laurence Reid at 617 370 8701 or check out https://www.decibeltx.com.Decibel Therapeutics Investment Alerts
| Decibel Therapeutics is not yet fully synchronised with the market data | |
| Decibel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (63.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Decibel Therapeutics currently holds about 125.65 M in cash with (56.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 62.0% of the company shares are held by institutions such as insurance companies |
Decibel Therapeutics Upcoming and Recent Events
Earnings reports are used by Decibel Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 8th of November 2023 Upcoming Quarterly Report | View | |
| 12th of March 2024 Next Financial Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of June 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Decibel Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 127.14 M.Decibel Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Decibel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Decibel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Decibel Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kapusta Matthew C over a year ago Disposition of 10000 shares by Kapusta Matthew C of Decibel Therapeutics subject to Rule 16b-3 | ||
Gsk Plc over a year ago Conversion by Gsk Plc of 458487 shares of Decibel Therapeutics | ||
Mclaughlin Kevin F over a year ago Acquisition by Mclaughlin Kevin F of 5000 shares of Decibel Therapeutics subject to Rule 16b-3 | ||
Kapusta Matthew C over a year ago Acquisition by Kapusta Matthew C of 10000 shares of Decibel Therapeutics subject to Rule 16b-3 | ||
Laurence Reid over a year ago Acquisition by Laurence Reid of 195000 shares of Decibel Therapeutics subject to Rule 16b-3 | ||
John Lee over a year ago Acquisition by John Lee of 120000 shares of Decibel Therapeutics subject to Rule 16b-3 |
Decibel Therapeutics Outstanding Bonds
Decibel Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Decibel Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Decibel bonds can be classified according to their maturity, which is the date when Decibel Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Decibel Therapeutics Predictive Daily Indicators
Decibel Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Decibel Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Decibel Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Decibel Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Decibel shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Decibel Therapeutics. By using and applying Decibel Stock analysis, traders can create a robust methodology for identifying Decibel entry and exit points for their positions.
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. Decibel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 62 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Decibel Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
| All Next | Launch Module |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Decibel Stock
If you are still planning to invest in Decibel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Decibel Therapeutics' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |